PCSK9 Forum is made possible thanks to support from AstraZeneca, LIB Therapeutics, Novartis and Sanofi, all of whom have no influence or control over editorial content. More information is available here »

Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

Orion

PlayORION-1: inclisiran shows sustained LDL cholesterol lowering with 2 doses

ORION-1: inclisiran shows sustained LDL cholesterol lowering with 2 doses

ESC 2017: Further data from the ORION-1 trial, first reported earlier this year, showed a sustained and durable LDL cholesterol lowering response extending to Day 360 after one or two doses (1,2). Inclisiran is a novel siRNA inhibitor to PCSK9 which specifically targets intracellular PCSK9…

read more »
Posted on 31 August 2017 | Posted by Bertrand Cariou | Posted in Videos, European Society of Cardiology Congress 2017
PlayAnthony Wierzbicki, Guy’s & St Thomas’ Hospitals, London discusses the implications of key trials at AHA 2016

Anthony Wierzbicki, Guy’s & St Thomas’ Hospitals, London discusses the implications of key trials at AHA 2016

Anthony Wierzbicki, Guy’s & St Thomas’ Hospitals, London discusses the implications of key trials at AHA 2016 GLAGOV ORION

read more »
Posted on 9 December 2016 | Posted by Anthony Wierzbicki | Posted in Videos, American Heart Association Scientific Sessions 2016
ORION I: Durability of response with PCSK9 RNA interference agent

ORION I: Durability of response with PCSK9 RNA interference agent

The first in class PCSK9 RNA interference agent, inclisiran (previously known as ALN-PCSsc) showed sustained lowering of low-density lipoprotein cholesterol (LDL-C) on top of the standard of care including statins, according to early results from the ORION-1 study. Until recently, the main focus of therapeutic…

read more »
Posted on 16 November 2016 | Posted in American Heart Association Scientific Sessions 2016

About PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is a not-for-profit organisation established by leading researchers in the fields of atherosclerosis, lipids and cardiovascular disease. Our mission is to raise awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target.

Editorial Policy

Unless otherwise indicated, opinions expressed in the PCSK9 Education and Research Forum are those of the contributors. All patients should discuss their medication with their healthcare professional. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the PCSK9 Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.
Educational Partners and Supporters
AstraZeneca

AstraZeneca has provided a grant towards this independent project and has had no involvement in its creation or organisation

LIB Therapeutics

Novartis

Sanofi

© Copyright 2025 PCSK9 Forum. All rights reserved